KRAS Inhibitors Market Size, Share, and Trends 2024 to 2034

The global KRAS inhibitors market size accounted for USD 112.71 million in 2024, grew to USD 118.26 million in 2025 and is projected to surpass around USD 182.36 million by 2034, representing a healthy CAGR of 4.93% between 2024 and 2034.

  • Last Updated : 14 Jun 2023
  • Report Code : 3035
  • Category : Healthcare

KRAS Inhibitors Market Size and Forecast 2024 to 2034

The global KRAS inhibitors market size is estimated at USD 112.71 million in 2024 and is anticipated to reach around USD 182.36 million by 2034, expanding at a CAGR of 4.93% between 2024 and 2034.

KRAS Inhibitors Market Size 2024 To 2034

KRAS Inhibitors Market Key Takeaways

  • North America held the maximum revenue share in 2023.
  • Asia-Pacific is expected to expand at the fastest CAGR between 2024 and 2034.
  • By Cancer Type, the lung cancer segment captured the largest market share in 2023.
  • By End-Use, the cancer research centers segment registered the major revenue share in 2023.

Market Overview

KRAS, an oncogene, undergoes frequent mutations and is highly prevalent in pancreatic, colorectal, and non-small cell lung tumors. Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) are prevalent in solid tumors, particularly lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The sustained activation and signaling of KRAS play a critical role in these cancers, making it a promising target for therapeutic interventions. Currently, there are several KRAS inhibitors in development, including small molecule inhibitors and monoclonal antibodies. These drugs work by targeting the KRAS protein and inhibiting its activity, which in turn can slow or stop the growth of cancer cells.

KRAS Inhibitors Market Growth Factors

The rising prevalence of KRAS mutations in various types of cancers across the globe is anticipated to augment the growth of the KRAS inhibitors market during the forecast period. Additionally, the advancements in drug discovery and development are also likely to fuel the growth of the market in the near future. Significant progress has been made in understanding the biology of KRAS and developing technologies to target it. This has led to the identification of novel drug candidates and the advancement of clinical trials for KRAS inhibitors. Ongoing research and technological advancements are augmenting the development of more potent and selective KRAS inhibitors, contributing to the growth of the market in the years to come.

The rising government investments, biotechnological advancements, and the digitalization of health profiles have propelled the progress of personalization beyond therapy selection and into drug research, with the aim of improving healthcare outcomes. This growing trend reflects the faster translation of research discoveries into clinical practice. Also, significant progress has been made in the development of KRAS inhibitors, with several promising candidates in clinical trials. The discovery of novel inhibitors and the advancement in structure-based drug design have facilitated the development of effective KRAS inhibitors and opened up new avenues for market growth in the years to come.

Market Scope

Report Coverage Details
Market Size in 2024 USD 112.71 Million
Market Size by 2034 USD 182.36 Million
Growth Rate from 2024 to 2034 CAGR of 4.93%
Largest Market North America
Fastest Growing Market Asia Pacific
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Cancer Type and By End-Use
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa


Market Dynamics

Driver

Increasing ongoing clinical trials

The increasing clinical trials are anticipated to augment the growth of the KRAS inhibitors market within the estimated timeframe. For instance, Amgen sponsored a Phase 1b/2 clinical study (CodeBreak 101) that investigated the safety, pharmacokinetics, tolerability, and effectiveness of sotorasib as a monotherapy and in combination with other anti-cancer treatments in individuals with advanced solid tumors carrying the KRAS p.G12C mutation. Additionally, there was a Phase 2 trial evaluating the use of MRTX849 as a monotherapy and in combination with pembrolizumab, as well as a Phase 3 trial comparing the effectiveness of adagrasib in combination with pembrolizumab versus pembrolizumab plus chemotherapy in patients with advanced non-small cell lung cancer harboring the KRAS G12C mutation.

Further, A Phase 1/2 clinical trial, known as KRYSTAL-1, was sponsored by Mirati Therapeutics Inc. This trial focused on evaluating the use of MRTX849 in patients with advanced solid tumors carrying the KRAS G12C mutation. Additionally, Mirati Therapeutics Inc., in collaboration with Novartis, sponsored a Phase 1/2 trial named KRYSTAL 2. This trial investigated the combination of MRTX849 with TNO155 in patients with advanced solid tumors harboring the KRAS G12C mutation. Thus, this is likely to contribute to the growth of the KRAS inhibitors market during the forecast period.

Restraints

Difficulties in targeting the protein

Previous studies have examined the inhibition of downstream signaling pathways of KRAS, such as RAF/MEK/ERK and PI3K/AKT/mTOR pathways, but the outcomes have been unsatisfactory. One likely reason for this failure is the presence of multiple feedback mechanisms that regulate these pathways. Despite encouraging results from a phase II trial, the phase III SELECT-1 trial revealed that the combination of the MEK inhibitor selumetinib with docetaxel did not show improved progression-free survival (PFS) compared to chemotherapy alone in 510 patients with KRAS-mutated non-small cell lung cancer (NSCLC). Tackling this obstacle is a crucial focus as it has the potential to impede market growth during the forecast period.

Opportunities

Rising collaborations & partnerships among key players

The increasing collaborations and partnerships among companies are anticipated to create growth opportunities for the market in the years to come. For instance, in September 2020, Boehringer Ingelheim and Mirati Therapeutics, Inc. disclosed a clinical partnership aimed at assessing the effectiveness of combining BI 1701963, a SOS1::pan-KRAS inhibitor that targets KRAS regardless of mutation type, with MRTX849, a selective inhibitor specifically designed for the KRAS G12C mutation.

The collaboration aims to explore the potential of this combination therapy to offer improved and long-lasting responses for patients with lung and colorectal cancers who currently face limited treatment choices. Also, in November 2022, Incyte and Mirati Therapeutics, Inc. unveiled a clinical trial collaboration and supply agreement. The partnership aims to explore the potential of combining INCB99280, Incyte's small molecule PD-L1 inhibitor, with adagrasib, a selective inhibitor that targets the KRASG12C mutation. Therefore, this is likely to accelerate the growth of the market in the years to come.

Cancer Type Insights

The lung cancer segment held the largest market share in 2023. Lung cancer is one of the most common cancers associated with KRAS mutations. The high prevalence of KRAS mutations in lung cancer patients creates a significant market opportunity for KRAS inhibitors. Targeting these specific mutations can potentially provide effective treatment options for a substantial number of lung cancer patients. Lung cancer, particularly non-small cell lung cancer (NSCLC), is a challenging disease to treat, and there is a significant unmet medical need for effective therapies. KRAS inhibitors offer a promising approach to specifically target these mutations, addressing the unmet medical need in the treatment of KRAS-mutant lung cancer.

Furthermore, the growth of the lung cancer segment in the KRAS inhibitors market is also expected to be fueled by the growing focus on research for lung cancer treatments. Also, the increasing awareness of these therapies among physicians and researchers is projected to contribute significantly to the expansion of this segment within the specified forecast period.

End-User Insights

The cancer research centers segment held revenue share in 2023. This is owing to the increasing clinical research along with increasing partnerships among research institutes and biotech companies. For instance, in May 2023, Mirati Therapeutics, Inc., a biotechnology company in the commercial stage, and Sarah Cannon Research Institute (SCRI), a renowned oncology research organization specializing in community-based clinical trials, joined forces through a strategic partnership.

The objective of this collaboration is to enhance diversity in the recruitment practices of clinical studies. Also, the increasing funding by cancer institutes is likely to support the segmental growth of the market. For instance, in February 2023, the National Cancer Institute has planned to provide funding to support Waters' laboratory through a career development grant of approximately $587,000 over a period of three years. This grant aims to facilitate the testing of clinically relevant drugs that specifically target two prevalent KRAS mutations observed in pancreatic cancer. The drugs being investigated are innovative formulations that have not yet been published, and their efficacy will be assessed using cell lines and animal models.

Regional Insights

North America held the largest revenue share in 2023. US accounted for the largest share of the North America KRAS inhibitors market. This is owing to the increasing prevalence of cancer in the region. Among all lung cancer diagnoses, non-small cell lung cancer (NSCLC) represents approximately 81%. It is estimated that in 2023, about 238,340 adults (117,550 men and 120,790 women) will receive a lung cancer diagnosis in the United States alone. Globally, the number of new lung cancer cases in 2020 was estimated to be 2,206,771. It's important to note that these figures encompass both small cell lung cancer and NSCLC. Thus, this is increasing the demand for KRAS inhibitors therapies in the region. Furthermore, the presence of key competitors along with rising research has also contributed to the growth of the market in the region. Additionally, the availability of advanced infrastructure for healthcare is also likely to support the regional growth of the KRAS inhibitors market during the forecast period.

Asia-Pacific is expected to grow at the fastest CAGR during the forecast period. The increasing research and development along with investment in the healthcare infrastructure is anticipated to augment the regional growth of the KRAS inhibitors market during the forecast period. Furthermore, the growing demand for personalized medicine for effective treatment increasing along with the aging population is also likely to support the regional growth of the market in the years to come. Additionally, the advancement and rising focus on the development of biotechnology is also expected to fuel market growth in the region.

KRAS Inhibitors Market Companies

  • Amgen
  • Boehringer Ingelheim
  • BridgeBio Pharma
  • Erasca
  • Innovent Biologics, Inc.
  • Incyte
  • Mirati Therapeutics
  • Novartis
  • Jemincare
  • Cardiff Oncology, Inc.

Recent Developments

  • In April 2023, Innovent Biologics, Inc. unveiled the latest findings of the phase 1 clinical trial (NCT05005234) for IBI351 (GFH925), a KRASG12C inhibitor. These updated results were presented orally during the 2023 American Association for Cancer Research (AACR) Annual Meeting.
  • In June 2022, Erasca, Inc., a clinical-stage company specializing in precision oncology, with a specific focus on the development and commercialization of therapies for patients suffering from RAS/MAPK pathway-driven cancers, revealed plans for a trial. This trial aims to explore the potential of combining the KRAS G12C inhibitor with the ERK1/2 inhibitor ERAS-007 in the treatment of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) driven by the KRAS G12C mutation.
  • In January 2022, BridgeBio Pharma, Inc. disclosed a non-exclusive clinical collaboration with Amgen Inc. (Amgen) aimed at assessing the combination of BBP-398, an SHP2 inhibitor with the potential to be a leading candidate, along with LUMAKRAS (sotorasib), a KRASG12C inhibitor. The collaboration focuses on patients with advanced solid tumors carrying the KRAS G12C mutation.
  • In February 2021, Mirati Therapeutics and the University of Texas MD Anderson Cancer Center, Inc. jointly announced a strategic collaboration in research and development. The collaboration aims to broaden the assessment of Mirati's two investigational KRAS inhibitors - adagrasib (MRTX849) in clinical development, and MRTX1133 in preclinical development. These inhibitors, which target two commonly occurring KRAS mutations in cancer, will be evaluated both as monotherapy and in combination with other agents.

Segments Covered in the Report:

By Cancer Type

  • Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Others

By End-Use

  • Clinic Laboratories
  • Cancer Diagnostic Centers
  • Hospitals
  • Cancer Research Institutes
  • Academic Institutions
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global KRAS inhibitors market size was valued at USD 112.71 million in 2024 and it is expected to reach around USD 182.36 million by 2034.

The global KRAS inhibitors market will register growth rate of 4.93% between 2024 and 2034.

The major players operating in the KRAS inhibitors market are Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, Inc., Incyte, Mirati Therapeutics, Novartis, Jemincare, Cardiff Oncology, Inc.,

The driving factors of the KRAS inhibitors market are the increasing ongoing clinical trials and the increasing focus and shift towards precision medicine.

North America region will lead the global KRAS inhibitors market during the forecast period 2024 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Meet the Team

Sanket Gokhale is one of the key authors contributing to the high-quality, actionable insights that define our market research reports. Sanket holds an MBA with a specialization in Healthcare Management, coupled with a Bachelor’s degree in Pharmacy. With over 5 years of experience in market research, Sanket has cultivated a deep understanding of the healthcare sector, from pharmaceutical innovations to healthcare

Learn more about Sanket Gokhale

With over 14 years of experience, Aditi is the powerhouse responsible for reviewing every piece of data and content that passes through our research pipeline. She is not just an expert—she’s the linchpin that ensures the accuracy, relevance, and clarity of the insights we deliver. Aditi’s broad expertise spans multiple sectors, with a keen focus on ICT, automotive, and various other cross-domain industries.

Learn more about Aditi Shivarkar

Related Reports